Dr. Richard M. Gewanter, MD

Dr. Gewanter practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Gewanter's NPI, 1992750582, was assigned on May 23, 2006. Dr. Gewanter graduated from Albert Einstein College of Medicine in 1995. Dr. Gewanter holds New York license 209945-1.

Dr. Gewanter's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Gewanter's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Dr. Gewanter is also affiliated with Mercy Hospital. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Gewanter to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gewanter practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Gewanter's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Gewanter is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Gewanter's licenses on file in 3 states: New York, Florida and Connecticut.

Dmand AI lists bladder cancer radiation, bone cancer radiation, brain cancer radiation, breast cancer radiation, lung cancer radiation and prostate cancer radiation among the conditions Dr. Gewanter treats.

CMS data shows 1,820 Medicare services from Dr. Gewanter across 18 procedure codes in 2024, for 329 Medicare patients. Medicare paid $171,107 for them. Every service was in an office.

CMS counts 329 Medicare patients who saw Dr. Gewanter in 2024. The largest group is 65 to 74, with 157 patients. 75% of them have cancer, and 75% have high blood pressure. 11% are also on Medicaid. Their average risk score is 2.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gewanter's median patient age at 74, with 26% women.

In 2024, Dr. Gewanter wrote 183 Medicare Part D claims for 72 patients. 93% of them were for generic drugs. CMS names the drug for 99 of them, across 3 drugs with 11 or more claims each, at $1,081 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Gewanter for performance year 2024, reported as part of a group. Dr. Gewanter accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gewanter as offering telehealth.

Dmand AI links 15 papers to Dr. Gewanter, published from 2015 to 2023. 2020 was the busiest year, with 4. The most frequent topics are Prostate-Specific Antigen, Prostatic Neoplasms and Radiotherapy, Intensity-Modulated. Dr. Gewanter has published most often in Int J Radiat Oncol Biol Phys. Dr. Gewanter's most frequent co-authors are Borys R. Mychalczak, MD, Marisa A. Kollmeier, MD and Michael J. Zelefsky, MD.

Dmand AI lists 2 awards for Dr. Gewanter, most recently Newsday - Top Doctors on Long Island in 2014.

Dr. Gewanter graduated from Albert Einstein College of Medicine in 1995.

Dr. Gewanter is in network with 13 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.